Several therapeutic approaches have been developed to improve the outcome among
patients with acute coronary syndrome (ACS). However, treatment with antithrombotic …

The standard approach to preventing acute coronary syndromes (ACSs) has been to inhibit
platelet aggregation with aspirin and to inhibit blood coagulation with low molecular-weight …

Clopidogrel is well established in the treatment of acute coronary syndromes and is
ubiquitous in cardiology practice. Landmark studies have established the importance of …

Atherothrombosis is the underlying pathology of the acute coronary syndromes (ACS), in
which platelet activation plays a key role. Therefore, antiplatelet therapy is an essential …

Clopidogrel has demonstrated improved outcomes for patients with acute coronary
syndromes in several large randomized controlled trials. However, some questions exist …

A comprehensive appraisal was undertaken on behalf of the British Cardiac Society and the
Royal College of Physicians of London to assess the use of clopidogrel in acute coronary …

An important part of the therapy management of acute coronary syndrome (ACS) consists of
antiplatelet drugs. Whereas the administration of acetylsalicylic acid (ASA) is well …

Despite many recent advancements in the treatment of coronary heart disease, it continues
to be an important source of patient morbidity and mortality as well as a significant source of …

Acute coronary syndromes (ACS) are the most common cause of death worldwide. In the
United States, over 1,500,000 patients with an ACS are discharged annually (1). ACS is …

Background: Despite significant advances in the management of coronary heart disease,
myocardial infarction (MI) is still associated with a mortality rate of 45%. Acetylsalicylic acid …